Isomorphic Laboratories (often referred to as Isomorphic Labs) is an artificial intelligence-driven drug discovery company headquartered in London, United Kingdom, with a significant research hub in Lausanne, Switzerland. Founded in 2021 by Sir Demis Hassabis, who also co-founded Google DeepMind and received the 2024 Nobel Prize in Chemistry, the company operates as an autonomous subsidiary under Alphabet Inc. (the parent company of Google).
The name "Isomorphic" is derived from the Greek terms for "same shape," reflecting the company's core philosophy: there is an underlying functional symmetry between the world of biology and the world of information science. Isomorphic Labs treats biology as a complex information processing system, aiming to use "digital biology" to model, understand, and eventually solve some of the world's most devastating diseases.
The Isomorphic Drug Design Engine (IsoDDE)
At the heart of the company?s operations is its proprietary Drug Design Engine, a unified computational platform that integrates various AI models to reimagine the drug discovery pipeline from first principles.
1. Building Beyond AlphaFold 3
While the company collaborated with Google DeepMind to develop AlphaFold 3?a revolutionary model that predicts the 3D structures and interactions of proteins, DNA, RNA, and ligands?Isomorphic Labs has since evolved the technology into a specialized commercial engine.
* Binding Affinity Prediction: In February 2026, the company announced that its updated engine more than doubled the performance of AlphaFold 3 on protein-ligand benchmarks. It can now predict the binding strength (affinity) of small molecules to target proteins with accuracy exceeding traditional, expensive physics-based methods.
* Complex Biologics: The engine provides a significant "step-change" in modeling antibody-antigen interfaces, specifically the CDR-H3 loop, which is the most variable and difficult part of an antibody to predict. This allows for the de novo design of entirely new therapeutic antibodies.
* High-Speed Simulation: The platform allows scientists to transition from "wet lab" experiments to "in silico" (virtual) simulations, reducing the time required to characterize molecular complexes from years to seconds.
2. Multi-Modality Capabilities
Unlike traditional biotech firms that specialize in one type of medicine, Isomorphic Labs' AI-first approach allows it to design candidates across several modalities:
* Small Molecules: Traditional chemical drugs (e.g., aspirin).
* Biologics: Complex, large-molecule medicines (e.g., insulin or monoclonal antibodies).
* Peptides & Molecular Glues: Novel classes of drugs that can target proteins previously considered "undruggable."
Products and Services
Isomorphic Labs does not sell software as a retail product; instead, it offers strategic research collaborations and maintains an internal drug candidate pipeline.
1. Strategic Research Partnerships
The company partners with global pharmaceutical giants to tackle high-value, "difficult-to-drug" targets. These deals typically involve significant upfront payments, research funding, and billions in potential milestone payments plus royalties.
* Novartis Partnership: Initially focused on small molecules for three challenging targets, this collaboration was expanded in 2025 to include additional research programs.
* Eli Lilly and Company: A multi-target collaboration leveraging the Isomorphic engine to discover small molecule therapeutics.
* Johnson & Johnson (J&J): A cross-modality research collaboration announced in early 2026 to design both small and large molecules for complex disease areas.
2. Internal Drug Pipeline
Isomorphic Labs is increasingly developing its own proprietary portfolio of drug candidates.
* Focus Areas: The internal pipeline is primarily concentrated on Oncology (cancer) and Immunology.
* Value Prop: By owning the assets from the discovery phase, the company aims to move from being a technology provider to a fully integrated biopharmaceutical entity.
3. AlphaFold Server (Non-Commercial Access)
In collaboration with Google DeepMind, the company supports the AlphaFold Server. While commercial drug design is restricted to Isomorphic's proprietary engine, this free service allows the global academic community to predict biological structures, fostering a wider ecosystem of "AI-native" biologists who may eventually join or partner with the firm.
Leadership and Expertise
The company employs over 300 experts across machine learning, medicinal chemistry, structural biology, and software engineering.
* Demis Hassabis (Founder & CEO): Nobel Laureate and pioneer of modern AI.
* Max Jaderberg (President): Former Chief AI Officer, leading the machine learning strategy.
* Miles Congreve (Chief Scientific Officer): A veteran medicinal chemist who has contributed to over 20 clinically evaluated drugs.
Funding and Financials
As of 2025, Isomorphic Labs transitioned from being a purely Alphabet-funded "bet" to securing external capital.
* $600 Million Funding Round: In March 2025, the company raised significant capital led by Thrive Capital, with participation from GV (Google Ventures) and Alphabet.
* Revenue Generation: The company generates revenue through its multi-billion dollar partnership agreements with the "Big Pharma" sector, positioning it as one of the most well-capitalized TechBio companies in the world.
Please note: This information is generated by AI. For legal use, verify with company sources.
